Lepu Medical Technology (Beijing) Co., Ltd.   Report issue

For profit Phase 4
Founded: Beijing China (1999)

Organization Overview

First Clinical Trial
2020
NCT04624854
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Lepu Medical Technology (Beijing) Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (2)

acetylsalicylic acid (aspirin) (2 trials)

clopidogrel (plavix) (2 trials)

Drugs in Other Trials (1)

ticagrelor (brilinta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Arterial Occlusive Diseases (Phase 4)

Arteriosclerosis (Phase 4)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Heart Diseases (Phase 4)

Myocardial Ischemia (Phase 4)

Syndrome (Phase 4)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3